Abstract
The benzodiazepine midazolam is widely used in critical care medicine. Midazolam has a clinically active metabolite, 1-hydroxymidazolam. The contribution of 1-hydroxymidazolam to the effects of midazolam is controversial. The aim of the current study was to compare the actions of midazolam and 1-hydroxymidazolam on network activity of cortical neurons. Midazolam depressed neuronal activity at a low concentration of 5 nM. When midazolam concentration was increased, it depressed neuronal discharge rates in a biphasic manner. In comparison, 1-hydroxymidazolam did not depress the cortical network activity at low nanomolar concentrations. Higher concentrations of 1-hydroxymidazolam consistently inhibited neuronal activity. Moreover, midazolam shortened cortical up states at low, but not at high concentrations, while the opposite effect was observed with 1-hydroxymidazolam. The network depressant action of midazolam at low concentrations was absent in slices from GABAA receptor α1(H101R)mutant mice. The α1(H101R)mutation renders α1-subunit containing GABAA receptors insensitive towards benzodiazepines. This GABAA receptor subtype is thought to mediate sedation. As midazolam is more potent than its metabolite 1-hydroxymidazolam, the major clinical effects are thus likely caused by midazolam itself. However, 1-hydroxymidazolam could add to the effects of midazolam, especially after the application of high doses of midazolam, and in case of impaired drug metabolism.
Similar content being viewed by others
Introduction
Midazolam is a commonly used benzodiazepine in anaesthesia and intensive care medicine. Midazolam has a clinical active metabolite: 1-hydroxymidazolam, which is, like the parent drug midazolam a neuronal depressant drug. However, 1-hydroxymidazolam’s contribution to the depression of neuronal activity and thus its clinical relevance still remains a matter of debate. There are numerous studies in which the statements concerning the contribution of 1-hydroxymidazolam to the clinical actions of midazolam range from “almost equipotent” to “no major contributing factor”1,2,3,4,5. In addition, Crevoisier et al. have demonstrated that cognitive and motor impairments induced by midazolam are different after oral or intravenous application, an observation that was attributed to the relatively higher amount of 1-hydroxymidazolam after oral administration6.
The current study was therefore designed to directly compare the effects of midazolam and 1-hydroxymidazolam on the activity of neocortical neurons in organotypic slice cultures, a model system in which, to the best of our knowledge, there is no relevant metabolism from midazolam to 1-hydroxymidazolam.
Basically, benzodiazepines like midazolam predominantly act via GABAA receptors harbouring either an α1, α2, α3 or α5-subunit. About 40% of all GABAA receptors in the brain contain α1-subunits, making them the major GABAA receptor subtype in the brain7. Mice carrying a point mutation in the α1 subunit of the GABAA receptor at position 101 are resistant to the sedative action of diazepam, indicating that benzodiazepine-induced sedation is predominantly mediated via GABAA receptors containing the α1-subunit8, 9. Moreover, it was suggested that sedation with diazepam depends on GABAA receptors located on glutamatergic neurons in the cerebral cortex10. On the cellular level, this molecular action of diazepam translates into a significant depression of cortical network action potential firing11. Therefore, in order to examine the contribution of α1-containing GABAA receptors to this phenomenon, in the current study clinically relevant concentrations of midazolam were also tested in neocortical slice cultures from GABAA receptor α1(H101R) knock-in mice.
Results
Neuronal activity of organotypic neocortical slice cultures under control conditions
Spontaneous firing patterns from neocortical organotypic slice cultures were characterized by phases of high neuronal activity (up states) separated by periods of neuronal silence. A typical extracellular recording is displayed in Fig. 1. To analyse changes of discharge rates in the presence of drugs we used the following parameters: i) the action potential firing rate and ii) the length of up states. Up states of neocortical slice cultures are characterized by high frequency action potential firing at the beginning of the up state, which is then gradually decreasing over time12. The median of the spontaneous action potential firing rate (in C57/BL6J mice) was at 10.12 Hz; interquartile range (iqr): 12.92; (number of recordings n = 481).
Effects of midazolam in organotypic slice cultures (C57BL/6J)
Midazolam in a concentration range from 5 nM to 100 µM inhibited the neuronal firing rate in a biphasic manner. From 5 nM to 1 µM, midazolam significantly depressed action potential firing. However, the inhibitory action of midazolam did not rise continuously with increasing concentrations. Actually, 500 nM and 1 µM midazolam depressed the neuronal activity only slightly less than the administration of 100 nM midazolam. Though, raising the concentration of midazolam to 25 µM and beyond led to a stronger depression, which was significantly different from the concentration range of 5 nM to 1 µM (Fig. 2A, Kruskal-Wallis test and post-hoc Bonferroni analysis).
Even a low concentration of 5 nM midazolam induced a significant change in neuronal activity (median 76%, iqr 26%; p < 0.001; n = 28; Mann-Whitney U test).
To further elucidate the actions of midazolam at 5 nM we calculated a peri-event time histogram (PETH) for the first 1000 ms of the average up state. The sham application of ACSF only led to negligible changes at the beginning of the up states (Fig. 2B). By comparison, 5 nM midazolam consistently inhibited action potential firing significantly over the entire first 1000 ms of the average up state (Fig. 2C).
To test whether this action of midazolam is mediated via the classical benzodiazepine binding site of the GABAA receptor, we performed experiments with flumazenil, a selective antagonist at the benzodiazepine binding site of the GABAA receptor13, 14. As shown in Fig. 2D,E the network depressing actions of midazolam (5 nM and 50 nM) indeed proved to be almost completely absent when administering 50 nM flumazenil.
Effects of 1-hydroxmidazolam in organotypic cultures and comparison to those of midazolam
To compare the actions of midazolam with those of 1-hydroxymidazolam we tested a concentration range of 1-hydroxymidazolam from 5 nM to 1 µM, because the in vivo concentration range of 1-hydroxymidazolam is lower than that of midazolam itself 3.
The concentration response relationship for 1-hydroxymidazolam is displayed in Fig. 3A. In contrast to midazolam, we could not find an inhibitory effect for 1-hydroxymidazolam at 5 nM and 50 nM. Only at concentrations of 100 nM or higher 1-hydroxymidazolam did induce a significant inhibition (median 60%, iqr 69; p < 0.001). Again, unlike midazolam, 1-hydroxymidazolam caused a steady increase in the depression of network activity with increasing concentrations of up to 1 µM (median 34%; iqr 33; p < 0.001).
To test whether the effect of 1-hydroxymidazolam is also mediated by the classical benzodiazepine binding site, we measured the network activity after administering a combination of 1 µM 1-hydroxymidazolam with 1 µM flumazenil. The depression of neocortical activity triggered by 1-hydroxymidazolam was almost completely antagonized by flumazenil (Fig. 3B).
To further explain the quantitative differences of action between the two compounds in detail, we calculated PETHs for 1-hydroxymidazolam. As can be seen in Fig. 3C, 1-hydroxymidazolam did not show any inhibitory effect at a concentration of 5 nM. At a higher concentration (100 nM), 1-hydroxymidazolam was able to depress cortical activity, but its effect was only significant during the first 100 ms of the up states (Fig. 3D). A comparison of the actions of the parent drug midazolam and its metabolite 1-hydroxymidazolam is displayed in Fig. 4. Due to the biphasic nature of midazolam’s concentration response curve, we compared only concentrations up to the border of the wide ‘plateau’ region of the concentration response curves (1 µM of both midazolam and 1-hydroxymidazolam). As can be seen in the plot (Fig. 4A), IC50 values of both concentration response curves differed by over an order of magnitude (IC50 in nM with 95% CI: midazolam, 3.6 [0.9 6.4]; 1-hydroxymidazolam: 84.2 [48.7 119.8]; extra sums-of-squares test (see Methods for details): F(2,242) = 11.98, p = 8.6 * 10−6).
To further investigate the differences in action of midazolam and 1-hydroxymidazolam we analysed the length of up states. Under control conditions, the median length of up states was 664 ms (iqr: 2400). When midazolam was administered at low concentrations, it shortened the length of up states, while at 500 nM and 1 µM this effect was completely absent. On the other hand, 1-hydroxymidazolam only reduced the length of up states significantly at 500 nM and 1 µM (Fig. 4B). It is obvious that midazolam and 1-hydroxymidazolam affected up state length in quite different ways: while midazolam shortened up state length particularly at concentrations below 0.5 µM, 1-hydroxymidazolam did so only at concentrations above 0.1 µM (Fig. 4B). Statistical analysis (see Methods) confirmed this impression (two-way ANOVA of Box-Cox transformed data, interaction effect: F(4,289) = 14.2, p = 1.4 * 10−10, eta squared with 95% CI = 0.15 [0.09 0.25]).
To further elucidate the actions of midazolam and 1-hydroxymidazolam at the synaptic level, we performed patch-clamp recordings in neocortical slice cultures from wild-type C57BL/6J mice. In a first set of experiments the effects on phasic inhibition were tested by recording miniature IPSCs from pyramidal neurons. To quantify drug actions on synaptical inhibition we used the total charge transfer, calculated as the area under the averaged IPSC multiplied by the frequency of IPSCs. Midazolam at a concentration of 50 nM increased total charge transfer by 71.6 ± 27.7% (n = 11, p = 0.045, t-test compared to sham application). At the same concentration, 1-hydroxymidazolam appeared to increase total charge transfer to a lesser extent, but this effect was not significant (40.4 ± 24.3%, n = 15, p = 0.22, t-test compared to sham application, see Fig. 5A,B). In a second set of experiments the actions of midazolam and 1-hydroxymidazolam on tonic inhibition were studied. For this purpose, neurons were additionally perfused with 20 µM bicuculline. Midazolam (50 nM) induced a tonic current of 16.87 ± 4.04 pA (n = 9, Fig. 5C,D), whereas 50 nM of 1-hydroxymidazolam induced a tonic current of 18.81 ± 4.57 pA (n = 12). However, both values were not significantly different from the basic tonic current induced in the presence of bicuculline and sham application (14.04 ± 5.87 pA, n = 7, one-way ANOVA, Fig. 5C,D).
The role of α1-subunit containing GABAA receptors for the actions of midazolam
Previous studies showed that cortical GABAA receptors containing α1-subunits are an important target in mediating benzodiazepine-induced sedation9, 10, 15.
To test the impact of cortical α1-containing GABAA receptors for midazolam we carried out experiments in cortical cultures derived from GABAAR α1(H101R) knock-in mice, in which α1-containing GABAA receptors are insensitive to benzodiazepines, including midazolam16. The basal activity of cultures derived from α1(H101R)knock-in mice was 16.64 Hz; 14.87 (median, iqr, n = 136). This value was slightly higher than the value obtained with wild-type mice. However, when comparing PETH of the averaged up states, no differences could be detected between wild-type and α1(H101R) mice (Fig. 6A).
As can be seen in Fig. 6B,D, we were not able to determine any significant inhibitory effect in neocortical tissue cultures derived from α1(H101R)knock-in mice for concentrations of 5 nM and 10 nM midazolam, neither during up states nor for the overall action potential firing rate. Only at a concentration of 100 nM midazolam did induce significant depression during phases of high neuronal activity (Fig. 6C). The concentration response relationship (see Fig. 6D) illustrates that only 100 nM and 1 µM midazolam caused a significant reduction of the action potential firing rate (median 64%; iqr 33; p < 0.001; median 63%; iqr 52; p = 0.001; Mann-Whitney U test). When comparing the effects of midazolam in α1(H101R) mice to those seen in wild-type mice, we observed that the inhibitory action of midazolam once again did not increase steadily with increasing concentrations. The concentration response relationship curves nearly run parallel to each other (Fig. 6E).
Discussion
Midazolam is metabolized into an active metabolite, 1-hydroxymidazolam. However, 1-hydroxymidazolam’s contribution to the neuronal depressant actions of midazolam is complex and still poorly understood1,2,3,4,5.
Within the central nervous system the neocortex seems to be the major target in mediating sedation by benzodiazepines10, 17. However, to date only little is known about the potentially differential effects of midazolam and 1-hydroxymidazolam on neuronal activity in this region of the brain. Therefore, in the present study we set out to compare the potency and characteristics of midazolam and 1-hydroxymidazolam to inhibit spontaneous cortical activity. We observed that midazolam, acting mainly via α1-containing GABAA receptors, is by far more potent than 1-hydroxymidazolam and that midazolam and 1-hydroxymidazolam act quantitatively and qualitatively different.
Midazolam depresses cortical activity in a biphasic manner. This is in close agreement with results obtained from previous studies with diazepam11, 14. The most convincing hypothesis to explain this biphasic depression is the existence of at least two benzodiazepine binding sites, as proposed by Walters et al., leading to two separate mechanisms of benzodiazepine action14.
The first phase of midazolam’s action (steady state of depression) is in line with previous studies18, 19 and this “ceiling effect” could be one of the reasons for the clinical safety of benzodiazepines. There are, however, several possibilities to explain this finding: First, a saturation at the classical benzodiazepine site11 and second, a novel binding site for benzodiazepines at the GABAA receptor, preventing further depression, as suggested in a previous study by Baur et al.20.
In accordance with previous clinical investigations and in vivo studies showing that sedation and changes of EEG frequencies could be induced by 1-hydroxymidazolam alone1, 2, 21 we found that 1-hydroxymidazolam inhibits neocortical network firing.
When comparing midazolam with 1-hydroxymidazolam it is evident that 1-hydroxymidazolam is far less potent. Inhibitory actions of 1-hydroxymidazolam could be observed starting at a concentration of 100 nM, corresponding to a plasma concentration of nearly 40 ng/ml. Considering the plasma concentration measured in a previous study3, 1-hydroxymidazolam may, therefore, contribute to the effects of midazolam, above all, in cases of deep sedation or in patients with severe renal dysfunction22. A summary of clinical and experimental findings concerning effects of midazolam and 1-hydroxymidazolam at different concentrations can be found in Table 1.
In addition, we detected that midazolam administered at the low concentration of 5 nM caused a significant inhibition of the cortical network activity in cultures from wild-type, but not from α1(H101R)knock-in mice. Therefore it seems reasonable to assume that midazolam at low nanomolar concentrations predominantly acts via α1-containing GABAA receptors. Thus, despite being a non-GABAA receptor subtype-selective benzodiazepine23, midazolam’s sedative actions are largely mediated by α1-containing GABAA receptors. In contrast to diazepam, at recombinant receptors midazaolam displays a preference for α1-containing GABAA receptors over α2-containing GABAA receptors: a recent study showed an approximately two-fold larger potentiation of GABA-induced currents by midazolam at GABAA receptors containing α1-subunits compared with GABAA receptors containing α2-subunits, whereas diazepam potentiated both receptor subtypes to a similar extent16.
To date, α1-containing GABAA receptors have been shown to be of major importance for mediating sedation, amnesia and anticonvulsant activity of benzodiazepines16, 24. Due to midazolam’s high efficacy at this GABAA receptor subtype, changes in quantity or distribution of this receptor subtype might have some clinical implications. For example, there is growing evidence that inflammation changes GABAA receptor composition in the brain. Pribiag and Stellwagen demonstrated that TNFα decreases inhibitory synaptic strength by downregulation of cell-surface levels of GABAA receptors25. In addition, interleukin-1β increases surface expression of α5-containing GABAA receptors and a tonic current generated by these receptors, resulting in memory deficits26. Furthermore, it is known that assembling, trafficking, clustering and endocytosis of GABAA receptors are highly dynamic and, thus, can be influenced by other factors like repeated seizures or alcohol abuse27. These changes in GABAA receptor populations might well be contributing to the high variability of duration and the different qualities of sedation with midazolam. Considering that midazolam shows a preference especially for α1-subunit containing GABAA receptors, small changes in the cell surface concentration of this GABAA receptor subtype may have major implications for midazolam’s clinical actions.
Moreover, there is evidence indicating that the addictive properties of benzodiazepines are mediated via α1-containing GABAA receptors28, 29. Finally, α1-subunits containing GABAA receptors are involved in developmental plasticity. The present ex vivo results raise questions regarding the potential induction of undesired long-term changes by midazolam in immature neuronal networks30.
In summary, midazolam depresses cortical networks at the low concentration of 5 nM, predominantly mediated via α1-containing GABAA receptors. This GABAA receptor subtype is the major molecular target of benzodiazepines for sedation. Small changes of this receptor population, e.g., due to inflammatory diseases, may therefore serve as an explanation for the large variability of midazolam’s clinical properties.
Midazolam’s main metabolite, 1-hydroxymidazolam, is far less potent than midazolam itself. The qualitatively different actions of 1-hydroxymidazolam compared with those of midazolam might argue for differential affinities of these two drugs at the α1 GABAA receptor subtype, possibly also at different GABAA receptor subtypes, as has recently been described for clobazam and its metabolite N-desmethyl-clobazam31.
We conclude that when considering the clinically relevant concentrations of midazolam, used for sedation in intensive care medicine, midazolam is clearly more potent than its metabolite, i.e. the major clinical effects are caused by the parent drug midazolam itself, presumably acting on cortical neurons. The higher potency of 1-hydroxymidazolam seen in some in vivo studies could be due to other types of GABAA receptors in lower brain structures, i.e. δ-subunit containing GABAA receptors.
Methods
Organotypic slice cultures
All procedures were approved by the Animal Care Committee (Eberhard Karls University, Tübingen, Germany) and were in accordance with the institutional and federal guidelines of the German Animal Welfare Act (TierSchG). Wild-type C57BL/6J mice and GABAA receptor α1(H101R)mutant mice on C57BL/6J background15 of both sexes were used. Neocortical organotypic slice cultures were prepared from three to five day old mice as described before32. In brief, animals were deeply anaesthetized with isoflurane and then decapitated. Cortical hemispheres were removed aseptically and 300 µm thick coronal slices were cut. Slices were fixed on glass coverslips by means of a plasma clot, transferred into plastic tubes containing each 750 µL of nutrition medium, to be then incubated in a roller drum at 37 °C. After 1 day in culture, antimitotics (10 µM 5-fluoro-2′-deoxyuridine, 10 μM ARA-c and 10 μM uridine) were added. The suspension was renewed twice a week.
Electrophysiology
Extracellular multi-unit recordings were performed in a recording chamber mounted on an inverted microscope. Slices were perfused with artificial cerebrospinal fluid (ACSF) consisting of (in mM) NaCl 120, KCl 3.5, NaH2PO4 1.13, MgCl2 1.0, NaHCO3 26, CaCl2 1.2, and glucose 11; then bubbled with 95% oxygen and 5% carbon dioxide. All experiments were conducted at 34 °C. For this purpose, a heating wire was glued onto a metal frame of the recording chamber and then heated using a direct current. ACSF-filled glass electrodes with a resistance of 3 to 5 MΩ were advanced into the tissue until extracellular multi-unit spike activity exceeding 100 µV in amplitude was visible. Data were acquired with the digidata 1200 AD/DA interface and AxoScope 9 software.
Intracellular voltage clamp recordings were performed on visually identified pyramidal neurons at room temperature. Pipettes were filled with a solution containing (in mM) 121 CsCL, 24 CsOH, 10 HEPES, 5 EGTA, 1 MgCl2 and 4 ATP, adjusted to pH 7.2 with 1 N HCl. Cells were voltage-clamped at −70 mV. To suppress glutamatergic synaptic transmission, we added 25 µM D-L-2-amino-5-phosphonopentanoic acid, 10 µM 6-cyano-7-nitroquinoxaline-2.3-dione and 1 µM tetrodotoxin. For the detection of tonic currents 20 µM bicuculline was added to the ACSF. Analysis of tonic currents followed the method proposed by Glykys and Mody33 and is described in detail in reference34.
Preparation and Application of Test Solutions
Midazolam and 1-hydroxymidazolam were dissolved in dimethyl sulfoxide to a 1 mM stock solution. Flumazenil was dissolved in 99% ethanol to a 5 mM stock solution. Drugs were diluted in ACSF to the tested concentration and filled into glass syringes immediately before the experiment was conducted. The drug containing ACSF was applied via bath perfusion using syringe pumps, connected to the experimental chamber via Teflon tubing. When switching from ACSF to drug-containing solutions, the medium was replaced by at least 95% within two minutes. To ensure steady-state conditions, recordings were conducted 12 minutes after commencing the change of the perfusate. Previous studies have demonstrated that this time interval is sufficient for steady-state conditions35, 36 because diffusion times in slice cultures are considerably shorter compared to acute slice preparations37, 38.
Data Analysis
Extracellular recorded signals were filtered and counted offline using self-written Matlab (R2008b) routines. The activity pattern of neocortical slice cultures was characterized by phases of spontaneous action potential firing (up states) separated by periods of neuronal silence. Action potentials were detected and the average firing rate was computed, using an automated event detection algorithm with a threshold set approximately 2 times higher than baseline noise. An up state was defined by an initial inter-event interval of 75 ms and a preceding silent period of at least 500 ms. All automated up state detection was checked by visual inspection based on field potentials. Parameters are shown as relative change compared to ACSF sham application. Each data set was checked for normal distribution by using qq plots. However, the hypothesis that data sets were normally distributed had to be rejected for the majority of these data sets. Therefore, grouped data are expressed as boxplots (line: median, box: lower quartile = 25th percentile and upper quartile = 75th percentile; whisker: 1.5*iqr (interquartile range); iqr: difference between the upper and the lower quartiles). For statistical analysis of extracellular detected neuronal spiking activity, we performed a combination of a non-parametric analysis of variance (Kruskal-Wallis test) and a multiple comparison post-hoc analysis (Bonferroni), followed by a Mann-Whitney U test to check for significant differences between the two groups.
To illustrate changes of the network firing, especially during phases of high neuronal activity (up states) peri-event time histograms (PETH) were calculated. For this purpose, the up states of every experimental condition were collected, divided into bins of 10 ms, and averaged. Because the length of up states was variable, the PETH were constrained to the first 1000 ms. To test for statistically significant effects, the effect size (Hedges’ g including the 95% confidence interval) was calculated. The 95% confidence interval excluding zero indicates significance at p < 0.05. A general rule of thumb says that absolute Hedges’ g values >0.8 indicate a strong effect and values >0.5 indicate a medium effect.
Statistical comparison of the actions of midazolam and 1-hydroxymidazolam
An extra sums-of-squares F test39 was performed to statistically compare IC50 values of the concentration-response relations of normalized firing rates for midazolam and 1-hydroxymidazolam. The underlying null hypothesis was that both data sets (midazolam and 1-hydroxymidazolam) stemmed from concentration-response relations with the same IC50. Briefly, Hill functions with three and two free parameters (‘full’ and ‘constrained’ models, respectively) were each fitted to each data set. In the constrained model, the IC50 (Kd) value was set to a fixed value, determined from a full Hill fit to the union of both data sets. An F value was computed as F = (SS1-SS2)/(DF1-DF2)/(SS2/DF2) where SS1 is the sum-of-squares of the constrained model (summed for both data sets), DF1 the degrees of freedom of the constrained model (again summed for both data sets), and SS2 and DF2 the equivalent values of the full model. From this F value (with DF1-DF2 and DF2 degrees of freedom for the numerator and denominator, respectively) a p value was computed, which specified the probability of obtaining data sets at least as extreme as the measured samples, given the null hypothesis.
As midazolam and 1-hydroxymidazolam altered up state length in qualitatively different ways, a fitting approach for statistical comparison of both drugs’ effects was not deemed reasonable. Instead, we opted for a two-way analysis of variance (ANOVA) with drug type (midazolam and 1-hydroxymidazolam) and drug concentration as the independent factors, focusing on their interaction. We computed both the p-value and eta squared, a measure of effect size, for the interaction of drug type with drug concentration. 95% confidence intervals of eta squared were computed by bootstrapping. Prior to analysis via ANOVA, the data were Box-Cox-transformed40 as the distribution of normalized burst length often had long tails towards high values: for each concentration of both drugs, the transformation parameter lambda was estimated; from the resulting collection of lambda values an average weighted by the number of samples in each group was computed (lambda = 0.214) and all data transformed with this value.
All analyses were implemented in Matlab (R2016b) and partly made use of the measure of effect size toolbox41.
References
Mandema, J. W. et al. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin. Pharmacol. Ther. 51, 715–728, doi:10.1038/clpt.1992.84 (1992).
Tuk, B., van Oostenbruggen, M. F., Herben, V. M., Mandema, J. W. & Danhof, M. Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam. J. Pharmacol. Exp. Ther. 289, 1067–1074 (1999).
Bremer, F., Reulbach, U., Schwilden, H. & Schuttler, J. Midazolam therapeutic drug monitoring in intensive care sedation: a 5-year survey. Ther. Drug Monit. 26, 643–649, doi:10.1097/00007691-200412000-00010 (2004).
Spina, S. P. & Ensom, M. H. Clinical pharmacokinetic monitoring of midazolam in critically ill patients. Pharmacotherapy 27, 389–398, doi:10.1592/phco.27.3.389 (2007).
Swart, E. L. et al. Population pharmacodynamic modelling of lorazepam- and midazolam-induced sedation upon long-term continuous infusion in critically ill patients. Eur. J. Clin. Pharmacol. 62, 185–194, doi:10.1007/s00228-005-0085-8 (2006).
Crevoisier, C., Ziegler, W. H., Eckert, M. & Heizmann, P. Relationship between plasma concentration and effect of midazolam after oral and intravenous administration. Br. J. Clin. Pharmacol. 16(Suppl 1), 51S–61S, doi:10.1111/bcp.1983.16.issue-S1 (1983).
Whiting, P. J. GABA-A receptor subtypes in the brain: a paradigm for CNS drug discovery? Drug Discov. Today 8, 445–450, doi:10.1016/S1359-6446(03)02703-X (2003).
Rudolph, U. et al. The GABAA a1-receptor mediates the sedative and amnestic, but not the anxiolytic, myorelaxant and ethanol-potentiating effects of diazepam. Pflügers Arch. 359, R 90 (1999).
McKernan, M. G. et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor a1 subtype. Nature Neurosci. 3, 587–592, doi:10.1038/75761 (2000).
Zeller, A. et al. Cortical glutamatergic neurons, mediate the motor sedative action of diazepam. Mol. Pharmacol. 73, 282–291, doi:10.1124/mol.107.038828 (2008).
Drexler, B., Zinser, S., Hentschke, H. & Antkowiak, B. Diazepam Decreases Action Potential Firing of Neocortical Neurons via Two Distinct Mechanisms. Anesth. Analg. 111, 1394–1399 (2010).
Drexler, B. et al. Enhancing the function of alpha5-subunit-containing GABAA receptors promotes action potential firing of neocortical neurons during up-states. Eur. J. Pharmacol. 703, 18–24, doi:10.1016/j.ejphar.2013.01.034 (2013).
Mohler, H. & Richards, J. G. Agonist and antagonist benzodiazepine receptor interaction in vitro. Nature 294, 763–765, doi:10.1038/294763a0 (1981).
Walters, R. J., Hadley, S. H., Morris, K. D. & Amin, J. Benzodiazepines act on GABAA receptors via two distinct and separable mechanisms. Nat. Neurosci. 3, 1274–1281, doi:10.1038/81800 (2000).
Rudolph, U. et al. Benzodiazepine actions mediated by specific g-aminobutyric acidA receptor subtypes. Nature 401, 796–800, doi:10.1038/44579 (1999).
Ralvenius, W. T., Benke, D., Acuna, M. A., Rudolph, U. & Zeilhofer, H. U. Analgesia and unwanted benzodiazepine effects in point-mutated mice expressing only one benzodiazepine-sensitive GABAA receptor subtype. Nat. Commun. 6, 6803, doi:10.1038/ncomms7803 (2015).
Heinke, W. & Koelsch, S. The effects of anesthetics on brain activity and cognitive function. Curr. Opin. Anaesthesiol. 18, 625–631, doi:10.1097/01.aco.0000189879.67092.12 (2005).
Bai, D. et al. Distinct functional and pharmacological properties of tonic and quantal inhibitory postsynaptic currents mediated by gamma-aminobutyric acid(A) receptors in hippocampal neurons. Mol. Pharmacol. 59, 814–824 (2001).
Yamada, J., Furukawa, T., Ueno, S., Yamamoto, S. & Fukuda, A. Molecular basis for the GABAA receptor-mediated tonic inhibition in rat somatosensory cortex. Cereb. Cortex 17, 1782–1787, doi:10.1093/cercor/bhl087 (2007).
Baur, R. et al. Covalent modification of GABAA receptor isoforms by a diazepam analogue provides evidence for a novel benzodiazepine binding site that prevents modulation by these drugs. J. Neurochem 106, 2353–2363, doi:10.1111/jnc.2008.106.issue-6 (2008).
Hotz, M. A., Ritz, R., Linder, L., Scollo-Lavizzari, G. & Haefeli, W. E. Auditory and electroencephalographic effects of midazolam and alpha-hydroxy-midazolam in healthy subjects. Br. J. Clin. Pharmacol. 49, 72–79, doi:10.1046/j.1365-2125.2000.00104.x (2000).
Bauer, T. M. et al. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet 346, 145–147, doi:10.1016/S0140-6736(95)91209-6 (1995).
Mathiasen, L. S., Rodgers, R. J. & Mirza, N. R. Comparative effects of nonselective and subtype-selective gamma-aminobutyric acidA receptor positive modulators in the rat-conditioned emotional response test. Behav. Pharmacol. 18, 191–203, doi:10.1097/FBP.0b013e32814fcdd4 (2007).
Rudolph, U., Crestani, F. & Mohler, H. GABA(A) receptor subtypes: dissecting their pharmacological functions. Trends Pharmacol. Sci. 22, 188–194, doi:10.1016/S0165-6147(00)01646-1 (2001).
Pribiag, H. & Stellwagen, D. TNF-alpha downregulates inhibitory neurotransmission through protein phosphatase 1-dependent trafficking of GABA(A) receptors. J. Neurosci. 33, 15879–15893, doi:10.1523/JNEUROSCI.0530-13.2013 (2013).
Wang, D. S. et al. Memory deficits induced by inflammation are regulated by alpha5-subunit-containing GABAA receptors. Cell Rep. 2, 488–496, doi:10.1016/j.celrep.2012.08.022 (2012).
Jacob, T. C., Moss, S. J. & Jurd, R. GABA(A) receptor trafficking and its role in the dynamic modulation of neuronal inhibition. Nat. Rev. Neurosci. 9, 331–343, doi:10.1038/nrn2370 (2008).
Heikkinen, A. E., Moykkynen, T. P. & Korpi, E. R. Long-lasting modulation of glutamatergic transmission in VTA dopamine neurons after a single dose of benzodiazepine agonists. Neuropsychopharmacology 34, 290–298, doi:10.1038/npp.2008.89 (2009).
Tan, K. R. et al. Neural bases for addictive properties of benzodiazepines. Nature 463, 769–774, doi:10.1038/nature08758 (2010).
Möhler, H., Fritschy, J. M., Crestani, F., Hensch, T. & Rudolph, U. Specific GABA(A) circuits in brain development and therapy. Biochem. Pharmacol. 68, 1685–1690, doi:10.1016/j.bcp.2004.07.025 (2004).
Ralvenius, W. T. et al. The clobazam metabolite N-desmethyl clobazam is an alpha2 preferring benzodiazepine with an improved therapeutic window for antihyperalgesia. Neuropharmacology 109, 366–375, doi:10.1016/j.neuropharm.2016.07.004 (2016).
Gähwiler, B. H. Organotypic monolayer cultures of nervous tissue. J. Neurosci. Methods 4, 329–342, doi:10.1016/0165-0270(81)90003-0 (1981).
Glykys, J. & Mody, I. The main source of ambient GABA responsible for tonic inhibition in the mouse hippocampus. J. Physiol 582, 1163–1178, doi:10.1113/jphysiol.2007.134460 (2007).
Grasshoff, C., Netzhammer, N., Schweizer, J., Antkowiak, B. & Hentschke, H. Depression of spinal network activity by thiopental: shift from phasic to tonic GABA(A) receptor-mediated inhibition. Neuropharmacology 55, 793–802, doi:10.1016/j.neuropharm.2008.06.026 (2008).
Antkowiak, B. Different actions of general anaesthetics on the firing patterns of neocortical neurons mediated by the GABAA receptor. Anesthesiology 91, 500–511, doi:10.1097/00000542-199908000-00025 (1999).
Dai, S., Perouansky, M. & Pearce, R. A. Amnestic Concentrations of Etomidate Modulate GABAA, slow Synaptic Inhibition in Hippocampus. Anesthesiology 111, 766–773, doi:10.1097/ALN.0b013e3181b4392d (2009).
Gredell, J. A., Turnquist, P. A., MacIver, M. B. & Pearce, R. A. Determination of diffusion and partition coefficients of propofol in rat brain tissue: implications for studies of drug action in vitro. Br. J. Anaesth. 93, 810–817, doi:10.1093/bja/aeh272 (2004).
Benkwitz, C. et al. Determination of the EC50 amnesic concentration of etomidate and its diffusion profile in brain tissue: implications for in vitro studies. Anesthesiology 106, 114–123, doi:10.1097/00000542-200701000-00020 (2007).
Motulsky, H. J. & Christopoulos, A. Fitting models to biological data using linear and nonlinear regression. A practical guide to curve fitting (Oxford University Press, 2004).
Box, G. E. P. & Cox, D. R. An analysis of transformations. Journal of the Royal Statistical Society B 26, 211–252, doi:10.1016/j.aca.2009.06.015 (1964).
Hentschke, H. & Stuttgen, M. C. Computation of measures of effect size for neuroscience data sets. Eur. J. Neurosci. 34, 1887–1894, doi:10.1111/j.1460-9568.2011.07902.x (2011).
Crevat-Pisano, P. et al. Plasma concentrations and pharmacokinetics of midazolam during anaesthesia. J. Pharm. Pharmacol. 38, 578–582, doi:10.1111/jphp.1986.38.issue-8 (1986).
Arendt, R. M., Greenblatt, D. J., Liebisch, D. C., Luu, M. D. & Paul, S. M. Determinants of benzodiazepine brain uptake: lipophilicity versus binding affinity. Psychopharmacology (Berl) 93, 72–76, doi:10.1007/BF02439589 (1987).
Acknowledgements
The authors would like to thank Claudia Holt and Ina Pappe for excellent technical assistance. The authors would also like to thank Sandra Schmidt for her linguistic assistance. This research was supported by the Deutsche Forschungsgemeinschaft (AN321/2-1). It had no involvement in data collection, study design, analysis or writing of the manuscript. UR was supported by Award Number R01GM086448 from the National Institute of General Medical Sciences. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of General Medical Sciences or the National Institutes of Health.
Author information
Authors and Affiliations
Contributions
M.B. helped to design the study, collected and analyzed the data and prepared the manuscript. U.R. helped to design the study and wrote the manuscript, B.A., B.D. and H.H. designed the study, analyzed the data and wrote the manuscript.
Corresponding author
Ethics declarations
Competing Interests
The authors declare that they have no competing interests.
Additional information
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Balk, M., Hentschke, H., Rudolph, U. et al. Differential depression of neuronal network activity by midazolam and its main metabolite 1-hydroxymidazolam in cultured neocortical slices. Sci Rep 7, 3503 (2017). https://doi.org/10.1038/s41598-017-03154-5
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-017-03154-5
This article is cited by
-
Safety, Pharmacokinetics, and Pharmacodynamics of Midazolam Gel After Rectal Administration in Healthy Chinese Subjects
Clinical Drug Investigation (2023)
-
Efficacy and safety of remimazolam tosylate for sedation during upper gastrointestinal endoscopy: study protocol for a multicenter randomized controlled trial
Trials (2022)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.